Literature DB >> 27656456

Hepatosplenic T Cell Lymphoma in an Immunocompetent Female Diagnosed using Flow Cytometry: A Rare Clinical Entity.

Pranav Dorwal1, Ritesh Sachdev2, Amit Pande3, Dharmendra Jain4, Bhawna Jha1, Vimarsh Raina5.   

Abstract

Hepatosplenic T-cell lymphoma is a rare haematopoietic malignancy that comprises less than 1% of Non-Hodgkin lymphomas. We are reporting a case of a 26-year-old female, who presented with pallor, weight loss, jaundice, pancytopenia and hepatosplenomegaly. The bone marrow examination showed infiltration by lymphoid cells. These cells on flow cytometric evaluation showed the phenotype of hepatosplenic T cell lymphoma. The cells were positive for CD3, CD8, CD56 and TCR γδ and negative for CD5, CD4, CD8, CD16, CD57, TCRαβ along with B cell markers. This case is reported for being a rare clinical entity and its presence in an immunocompetent female making it rarer.

Entities:  

Keywords:  Cluster of differentiation; Hepatosplenomegaly; Immunophenotyping; Pancytopenia

Year:  2016        PMID: 27656456      PMCID: PMC5028430          DOI: 10.7860/JCDR/2016/16943.8355

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  9 in total

1.  Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.

Authors:  Ann Corken Mackey; Lanh Green; Li-Ching Liang; Patricia Dinndorf; Mark Avigan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2007-02       Impact factor: 2.839

2.  Hepatosplenic T-cell lymphoma.

Authors:  Fahad I Alsohaibani; Maheeba A Abdulla; Mousa M Fagih
Journal:  Indian J Hematol Blood Transfus       Date:  2011-02-12       Impact factor: 0.900

3.  Hepatosplenic T-cell lymphoma: clinicopathologic, immunophenotypic, and molecular characterization of 17 Chinese cases.

Authors:  Chang-li Lu; Yuan Tang; Qun-pei Yang; Mi Wang; Sha Zhao; Cheng-feng Bi; Neng-gang Jiang; Wen-yan Zhang; Jian-ping Liu; Xia Xu; Wei-ping Liu
Journal:  Hum Pathol       Date:  2011-06-17       Impact factor: 3.466

Review 4.  A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.

Authors:  David S Kotlyar; Mark T Osterman; Robert H Diamond; David Porter; Wojciech C Blonski; Mariusz Wasik; Sami Sampat; Manuel Mendizabal; Ming V Lin; Gary R Lichtenstein
Journal:  Clin Gastroenterol Hepatol       Date:  2010-10-01       Impact factor: 11.382

Review 5.  Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990.

Authors:  E Weidmann
Journal:  Leukemia       Date:  2000-06       Impact factor: 11.528

6.  Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta.

Authors:  J P Farcet; P Gaulard; J P Marolleau; J P Le Couedic; T Henni; M F Gourdin; M Divine; C Haioun; S Zafrani; M Goossens
Journal:  Blood       Date:  1990-06-01       Impact factor: 22.113

Review 7.  Clinical features of non-Hodgkins lymphoma presenting with acute liver failure: a report of five cases and review of published experience.

Authors:  Christopher J Lettieri; Benjamin W Berg
Journal:  Am J Gastroenterol       Date:  2003-07       Impact factor: 10.864

8.  Hepatosplenic and other gammadelta T-cell lymphomas.

Authors:  Francisco Vega; L Jeffrey Medeiros; Philippe Gaulard
Journal:  Am J Clin Pathol       Date:  2007-06       Impact factor: 2.493

Review 9.  Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.

Authors:  Karim Belhadj; Felix Reyes; Jean-Pierre Farcet; Herve Tilly; Christian Bastard; Regis Angonin; Eric Deconinck; Frederic Charlotte; Veronique Leblond; Eric Labouyrie; Pierre Lederlin; Jean-Francois Emile; Beatrice Delmas-Marsalet; Bertrand Arnulf; Elie-Serge Zafrani; Philippe Gaulard
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.